Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Alcohol Use Disorder
100%
Laboratory Screening
100%
Human Laboratory
100%
Smokers
56%
Lorcaserin
50%
Semaglutide
50%
5-HT2C Receptor Agonist
18%
Alcohol-related
18%
Impulsivity
12%
Human Data
12%
Cigarette Smokers
12%
Health Risk
12%
Critical Groups
12%
Randomized Controlled Trial
12%
Within-subject
12%
5-hydroxytryptamine
12%
Nicotine
12%
Cigarette Smoking
12%
Alcohol Motives
12%
Pharmacotherapy Development
12%
Medication Development
12%
Societal Burden
12%
GLP-1 Receptor Agonist
12%
NIAAA
12%
Targeted Treatment
12%
Alcohol
12%
Health Burden
12%
Long-term Health
12%
Development Strategy
12%
5-HT2C Receptor
6%
Human Trials
6%
Glucagon
6%
Incretin Hormones
6%
5-HT System
6%
5-HT Receptors
6%
Public Health Impact
6%
Weight Management
6%
Addictive Drugs
6%
Placebo
6%
Phase II Clinical Trial
6%
Alcohol Reward
6%
Alcohol Reduction
6%
Dopamine Function
6%
Smoking Cessation
6%
Monotherapy
6%
Repurposing
6%
Glucagon-like peptide-1 Receptor (GLP-1R)
6%
Nicotine Reduction
6%
Addictive Behavior
6%
Treatment Mechanisms
6%
Alcohol Administration
6%
Human Participants
6%
Serotonin
6%
Behavioral Indices
6%
Motivation
6%
Use Reports
6%
Alcohol Intake
6%
Screening Method
6%
Balanced Design
6%
Medicine and Dentistry
Alcoholic Polyneuropathy
100%
Smoking
56%
Semaglutide
50%
5-HT Receptors
25%
Receptor
25%
Cigarette Smoking
25%
Health Hazard
12%
Impulsiveness
12%
Health Care Cost
12%
Targeted Therapy
12%
Glucagon-Like Peptide-1 Agonist
12%
Drug Therapy
12%
Randomized Controlled Trial
12%
Nicotine Withdrawal
6%
Glucagon
6%
Monotherapy
6%
Glucagon Like Peptide 1 Receptor
6%
Incretin
6%
Weight Management
6%
Serotonin
6%
Clinical Trial
6%
Public Health
6%
Placebo
6%
Screening
6%